Department of Gynaecology, Gelre Hospitals, Apeldoorn, The Netherlands.
Synapse Research Institute, Maastricht, The Netherlands.
Int J Lab Hematol. 2018 Jun;40(3):268-275. doi: 10.1111/ijlh.12775. Epub 2018 Jan 16.
Heavy menstrual bleeding (HMB) is a condition that affects 20%-30% of women of reproductive age. HMB has a multifactorial pathophysiology, which is incompletely understood. HMB symptoms are very common in patients with established haemostasis defects, likewise, women with heavy menstrual bleeding have a higher prevalence of impaired Von Willebrand factor (VWF) levels and function, thrombocytopenia, impaired platelet function and impaired coagulation. The aim of this study was to quantify the prevalence of impaired platelet function, impaired coagulation and reduced VWF activity in patients with HMB.
We have used thrombin generation (TG), a flow cytometry-based platelet function test and a flow cytometry-based VWF function test to study haemostasis in 58 women (median age: 48.4 years, range 40-60 years) with HMB. In addition, we determined VWF antigen levels and VWF ristocetin co-factor activity in platelet-poor plasma. Reference ranges of platelet function were measured in whole blood of 123 healthy volunteers, while reference ranges of TG were determined in platelet-poor plasma (PPP) of 126 healthy volunteers.
Fourteen (24%) patients with HMB had impaired platelet function and 17 (29.3%) patients had impaired coagulation. Five patients (8.6%) had both impaired platelet function and impaired coagulation. Only 2 (3.4%) patients had an impaired VWF function or levels; one of them was in combination with impaired coagulation.
Our approach in women with HMB using a high precision platelet function test in combination with thrombin generation showed impaired coagulation or impaired platelet function in more than 40% of the patients.
月经过多(HMB)是一种影响 20%-30%育龄期妇女的疾病。HMB 的病理生理学具有多因素性,目前尚未完全了解。在已确诊的止血缺陷患者中,HMB 症状非常常见,同样,月经过多的妇女也存在较高的血管性血友病因子(VWF)水平和功能受损、血小板减少、血小板功能受损和凝血功能受损的患病率。本研究旨在定量评估 HMB 患者血小板功能障碍、凝血功能障碍和 VWF 活性降低的发生率。
我们使用凝血酶生成(TG)、基于流式细胞术的血小板功能检测和基于流式细胞术的 VWF 功能检测来研究 58 例 HMB 患者的止血情况。此外,我们还测定了血小板减少血浆中的 VWF 抗原水平和 VWF 瑞斯托菌素辅因子活性。123 名健康志愿者全血的血小板功能参考范围,而 126 名健康志愿者血小板减少血浆(PPP)的 TG 参考范围。
14 例(24%)HMB 患者存在血小板功能障碍,17 例(29.3%)患者存在凝血功能障碍。5 例(8.6%)患者同时存在血小板功能障碍和凝血功能障碍。仅有 2 例(3.4%)患者存在 VWF 功能或水平异常;其中 1 例同时存在凝血功能障碍。
我们对 HMB 患者采用高精度血小板功能检测联合凝血酶生成的方法,结果显示超过 40%的患者存在凝血功能障碍或血小板功能障碍。